JP2016512230A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512230A5 JP2016512230A5 JP2015562555A JP2015562555A JP2016512230A5 JP 2016512230 A5 JP2016512230 A5 JP 2016512230A5 JP 2015562555 A JP2015562555 A JP 2015562555A JP 2015562555 A JP2015562555 A JP 2015562555A JP 2016512230 A5 JP2016512230 A5 JP 2016512230A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- parenteral composition
- use according
- levodopa
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WTDRDQBEARUVNC-LURJTMIESA-N 3-hydroxy-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 8
- 229960004502 levodopa Drugs 0.000 claims 8
- 229960004205 CARBIDOPA Drugs 0.000 claims 7
- TZFNLOMSOLWIDK-JTQLQIEISA-N Carbidopa Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 7
- 239000004475 Arginine Substances 0.000 claims 6
- 101700057431 PSMA2 Proteins 0.000 claims 3
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- JRURYQJSLYLRLN-BJMVGYQFSA-N Entacapone Chemical group CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N Tasmar Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims 1
- 229960003337 entacapone Drugs 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002459 sustained Effects 0.000 claims 1
- 229960004603 tolcapone Drugs 0.000 claims 1
Claims (12)
- パーキンソン病の治療用医薬を製造するための、カルビドパ、レボドパおよびＣＯＭＴ阻害薬の使用であって、
前記医薬が、組み合わせて投与される、単一の非経口組成物と経口組成物とを含むこと、ならびに
前記非経口組成物が、カルビドパおよびレボドパを含み、皮下投与用、経皮投与用、皮内投与用、静脈内投与用、筋肉内投与用、気管内投与用、鼻腔内投与用または髄腔内投与用として製剤化されており、前記経口組成物が前記ＣＯＭＴ阻害薬を含むことを特徴とする使用。 - 前記非経口組成物が、皮下投与用、経皮投与用または皮内投与用として製剤化される請求項１の使用。
- 前記非経口組成物が実質的に持続的な投与に適している請求項１の使用。
- 前記非経口組成物がアルギニンをさらに含む請求項１〜３のいずれか１項の使用。
- 前記非経口組成物におけるカルビドパおよびレボドパとアルギニンとのモル比が１：２〜１：３．５である請求項４の使用。
- 前記非経口組成物が（ｉ）アルギニン、０．１〜２重量％のカルビドパおよび４〜８重量％のレボドパを含むか、または（ｉｉ）アルギニン、０．６〜１．５重量％のカルビドパおよび６重量％のレボドパを含む請求項５の使用。
- 前記非経口組成物の投与が０．１〜１０００μＬ／時間／部位の速度で行われるか、２〜１０ｍＬ／２４時間／部位の量で行われるか、レボドパ８０〜８００ｍｇ／日およびカルビドパ２０〜２００ｍｇ／日の用量で行われるか、またはレボドパ２４０〜３６０ｍｇ／日／部位およびカルビドパ６０〜９０ｍｇ／日／部位の速度で行われる請求項６の使用。
- 前記非経口組成物の投与が４〜６ｍＬ／２４時間／部位の量で行われる請求項７の使用。
- 前記非経口組成物が（ｉ）アルギニン、１〜４重量％のカルビドパおよび６〜１６重量％のレボドパを含むか、または（ｉｖ）アルギニン、１．５〜２．５重量％のカルビドパおよび１２重量％のレボドパを含む請求項５の使用。
- 前記非経口組成物の投与が０．２〜２０００μＬ／時間／部位の速度で行われるか、１０〜２４ｍＬ／２４時間／部位の量で行われるか、レボドパ６００〜４０００ｍｇ／日およびカルビドパ６０〜５００ｍｇ／日の用量で行われるか、またはレボドパ８００〜１６００ｍｇ／日／部位およびカルビドパ２００〜４００ｍｇ／日／部位の速度で行われる請求項９の使用。
- 前記非経口組成物の投与が１２〜１６ｍＬ／２４時間／部位の量で行われる請求項１０の使用。
- 前記ＣＯＭＴ阻害薬がエンタカポンまたはトルカポンである請求項１〜１１のいずれか１項の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779357P | 2013-03-13 | 2013-03-13 | |
| US61/779,357 | 2013-03-13 | ||
| PCT/IL2014/050261 WO2014141261A1 (en) | 2013-03-13 | 2014-03-13 | Method for treatment of parkinson's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019008215A Division JP6625773B2 (ja) | 2013-03-13 | 2019-01-22 | パーキンソン病の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512230A JP2016512230A (ja) | 2016-04-25 |
| JP2016512230A5 true JP2016512230A5 (ja) | 2017-04-13 |
| JP6472391B2 JP6472391B2 (ja) | 2019-02-20 |
Family
ID=50513395
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562555A Active JP6472391B2 (ja) | 2013-03-13 | 2014-03-13 | パーキンソン病の治療方法 |
| JP2019008215A Active JP6625773B2 (ja) | 2013-03-13 | 2019-01-22 | パーキンソン病の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019008215A Active JP6625773B2 (ja) | 2013-03-13 | 2019-01-22 | パーキンソン病の治療方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20160022573A1 (ja) |
| EP (2) | EP2968218B1 (ja) |
| JP (2) | JP6472391B2 (ja) |
| KR (1) | KR102209353B1 (ja) |
| CN (2) | CN110935026A (ja) |
| AU (1) | AU2014229127B2 (ja) |
| BR (1) | BR112015022390A8 (ja) |
| CA (1) | CA2904838C (ja) |
| CL (1) | CL2015002641A1 (ja) |
| DK (1) | DK2968218T3 (ja) |
| ES (1) | ES2889626T3 (ja) |
| HR (1) | HRP20211442T1 (ja) |
| HU (1) | HUE056006T2 (ja) |
| IL (1) | IL266648B (ja) |
| MX (1) | MX365206B (ja) |
| PL (1) | PL2968218T3 (ja) |
| PT (1) | PT2968218T (ja) |
| RU (2) | RU2677278C2 (ja) |
| SG (2) | SG10201911731YA (ja) |
| WO (1) | WO2014141261A1 (ja) |
| ZA (1) | ZA201507621B (ja) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX364974B (es) | 2009-05-19 | 2019-05-16 | Neuroderm Ltd | Composiciones para la administracion continua de inhibidores de dopa descarboxilasa. |
| PL2640370T3 (pl) | 2010-11-15 | 2018-09-28 | Neuroderm Ltd | Kompozycje do dostarczania przezskórnego substancji czynnych |
| ES2776734T3 (es) | 2010-11-15 | 2020-07-31 | Neuroderm Ltd | Administración continua de L-dopa, inhibidores de dopa descarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para ello |
| MX2016011837A (es) * | 2014-03-13 | 2017-04-27 | Neuroderm Ltd | Composiciones de inhibidores de la dopa decarboxilasa. |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| HUE052857T2 (hu) | 2014-09-04 | 2021-05-28 | Lobsor Pharmaceuticals Ab | Levodopat, egy dopamin dekarboxiláz inhibitort és egy COMT inhibitort tartalmazó gyógyászati készítmények, és azok adagolási módszerei |
| KR102537018B1 (ko) | 2014-10-21 | 2023-05-30 | 애브비 인코포레이티드 | 카르비도파 및 l-도파 프로드럭 및 파킨슨병을 치료하기 위한 이들의 용도 |
| MA41377A (fr) | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
| US10555922B2 (en) | 2015-09-04 | 2020-02-11 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| WO2017070293A1 (en) * | 2015-10-20 | 2017-04-27 | Ironwood Pharmaceuticals, Inc. | Phosphodiesterase 9 inhibitor and levodopa therapy |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| WO2018224501A1 (en) * | 2017-06-05 | 2018-12-13 | Dizlin Pharmaceuticals Ab | Levodopa infusion solution |
| WO2019097120A1 (en) * | 2017-11-16 | 2019-05-23 | Orion Corporation | New use and pharmaceutical dosage forms |
| WO2019147934A1 (en) * | 2018-01-29 | 2019-08-01 | Sackner Bernstein Jonathan | Methods for dopamine modulation in human neurologic diseases |
| CA3095341A1 (en) * | 2018-03-29 | 2019-10-03 | Avion Pharmaceuticals, Llc | Levodopa fractionated dose composition and use |
| CN111701024B (zh) * | 2020-05-26 | 2022-05-24 | 上海京新生物医药有限公司 | 一种左旋多巴制剂及其制备方法及其应用 |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| WO2023282900A1 (en) * | 2021-07-08 | 2023-01-12 | Morehouse School Of Medicine | Method and system of diagnosing and treating neurodegenerative disease and seizures |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4832957A (en) * | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| FI109453B (fi) * | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| EP2050447B1 (en) * | 2005-06-08 | 2017-10-11 | Orion Corporation | An entacapone-containing oral dosage form |
| TR200806646A2 (tr) * | 2008-09-03 | 2009-06-22 | Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. | Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar |
| MX364974B (es) * | 2009-05-19 | 2019-05-16 | Neuroderm Ltd | Composiciones para la administracion continua de inhibidores de dopa descarboxilasa. |
| ES2776734T3 (es) * | 2010-11-15 | 2020-07-31 | Neuroderm Ltd | Administración continua de L-dopa, inhibidores de dopa descarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para ello |
-
2014
- 2014-03-13 CA CA2904838A patent/CA2904838C/en active Active
- 2014-03-13 EP EP14718177.0A patent/EP2968218B1/en active Active
- 2014-03-13 US US14/774,938 patent/US20160022573A1/en not_active Abandoned
- 2014-03-13 RU RU2015143112A patent/RU2677278C2/ru active
- 2014-03-13 SG SG10201911731YA patent/SG10201911731YA/en unknown
- 2014-03-13 ES ES14718177T patent/ES2889626T3/es active Active
- 2014-03-13 WO PCT/IL2014/050261 patent/WO2014141261A1/en active Application Filing
- 2014-03-13 CN CN201911315631.1A patent/CN110935026A/zh active Pending
- 2014-03-13 CN CN201480027268.2A patent/CN105209029A/zh active Pending
- 2014-03-13 BR BR112015022390A patent/BR112015022390A8/pt not_active Application Discontinuation
- 2014-03-13 MX MX2015012561A patent/MX365206B/es active IP Right Grant
- 2014-03-13 AU AU2014229127A patent/AU2014229127B2/en active Active
- 2014-03-13 DK DK14718177.0T patent/DK2968218T3/da active
- 2014-03-13 PT PT147181770T patent/PT2968218T/pt unknown
- 2014-03-13 HU HUE14718177A patent/HUE056006T2/hu unknown
- 2014-03-13 SG SG11201507538UA patent/SG11201507538UA/en unknown
- 2014-03-13 HR HRP20211442TT patent/HRP20211442T1/hr unknown
- 2014-03-13 JP JP2015562555A patent/JP6472391B2/ja active Active
- 2014-03-13 RU RU2018144700A patent/RU2018144700A/ru not_active Application Discontinuation
- 2014-03-13 PL PL14718177T patent/PL2968218T3/pl unknown
- 2014-03-13 KR KR1020157028984A patent/KR102209353B1/ko active IP Right Grant
- 2014-03-13 EP EP21176202.6A patent/EP3892266A1/en not_active Withdrawn
-
2015
- 2015-09-11 CL CL2015002641A patent/CL2015002641A1/es unknown
- 2015-10-13 ZA ZA2015/07621A patent/ZA201507621B/en unknown
-
2019
- 2019-01-22 JP JP2019008215A patent/JP6625773B2/ja active Active
- 2019-05-15 IL IL266648A patent/IL266648B/en active IP Right Grant
-
2020
- 2020-05-18 US US16/876,911 patent/US20210093560A1/en not_active Abandoned
-
2022
- 2022-03-18 US US17/698,189 patent/US20230047847A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512230A5 (ja) | ||
| PH12018550148A1 (en) | Hepatitis b antiviral agents | |
| PH12018550201A1 (en) | Hepatitis b antiviral agents | |
| PH12019502355A1 (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b | |
| PH12020550065A1 (en) | Hepatitis b antiviral agents | |
| CY1119433T1 (el) | Αμινο-υποκατεστημενες ιμιδαζοπυριδαζινες | |
| UA113165C2 (xx) | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
| JP2012527447A5 (ja) | ||
| RU2015143112A (ru) | Способ лечения болезни паркинсона | |
| MX2017009837A (es) | Dinucleotidos ciclicos utiles para el tratamiento de cancer entre otros. | |
| EA201591890A1 (ru) | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| PH12016500027B1 (en) | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| MX355742B (es) | Análogos deuterados del ácido 4-hidroxibutírico. | |
| JO3583B1 (ar) | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي | |
| MX359989B (es) | Fármacos antivirales para el tratamiento de la infección por arenavirus. | |
| MX2009008439A (es) | Nuevos inhibidores de la replicacion del virus de hepatitis c. | |
| MX2022009352A (es) | Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c. | |
| MX2018003569A (es) | Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos. | |
| MX2024006689A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| MY190867A (en) | ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment | |
| EP4389217A3 (en) | Use of ccr3-inhibitors | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| TW201613578A (en) | Pharmaceutical combinations | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. |